Ruptured Hepatocellular Carcinoma: Current Status of Research

By -

 

Executive Summary

Ruptured hepatocellular carcinoma (rHCC) is a critical, life-threatening complication of primary liver cancer characterized by high acute mortality rates ranging from 25% to 75%. While historically considered rare, its incidence is increasing, particularly in Asia, where it affects 10% to 15% of HCC patients. Emerging research and clinical observations suggest that the traditional classification of all rHCC cases as Stage T4 may be inaccurate, as aggressive intervention—specifically staged hepatectomy—can result in significantly better outcomes than previously believed.

The current clinical consensus is shifting toward a multidisciplinary approach. Emergency transcatheter arterial embolization (TAE) or chemoembolization (TACE) is frequently utilized to stabilize hemodynamics, followed by "staged" surgical resection once the patient’s condition and liver function have improved. This strategy has demonstrated a one-year overall survival rate as high as 88.7% in certain cohorts, challenging the nihilistic prognostic view of the disease.

Clinical Manifestations and Diagnostic Protocol

The diagnosis of rHCC requires rapid clinical assessment and a combination of laboratory and imaging techniques.

Clinical Presentation

Patients typically present to emergency departments with a combination of the following:

  • Peritonitis: Sudden severe epigastric pain, muscle tension, and rebound tenderness (observed in 66%–100% of cases).

  • Hemorrhagic Shock: Dizziness, restlessness, tachycardia, oliguria, and hypotension (observed in approximately 33% of cases).

  • Hemoperitoneum: Abdominal distension and the presence of non-coagulated blood upon diagnostic puncture.

  • Liver Stigmata: Jaundice, spider nevi, and other signs of underlying cirrhosis.

Diagnostic Imaging and Laboratory Evaluation

  • Ultrasound (US): A routine first-line tool with a detection rate of 90%–97% for abdominal organ issues. However, it is less effective for diagnosing rupture in patients with small tumor diameters.

  • Computed Tomography (CT): The superior technique for detecting rHCC. Contrast-enhanced CT helps localize the source of bleeding (hematomas with higher attenuation are typically closer to the source) and identifies extrahepatic tumor protrusion or discontinuous liver surfaces.

  • Laboratory Tests: Urgent examination of liver and kidney function, coagulation profiles (which are often impaired), and tumor markers like Alpha-fetoprotein (AFP) is essential for assessing the patient's baseline status.

Mechanisms of Spontaneous Rupture

The pathogenesis of spontaneous HCC rupture is multifactorial, involving both tumor-specific characteristics and systemic physiological conditions.

Factor Category

Description and Impact

Tumor Characteristics

Diameter >5–7 cm and protrusion >1 cm from the liver surface are high-risk indicators. Rapid growth and internal necrosis increase intratumoral pressure and venous congestion, leading to vascular dysfunction.

Vascular Brittle-ness

Chronic inflammation from Hepatitis B (Positive HBsAg) leads to antigen-antibody complexes depositing in small artery walls. This destroys vascular structures and increases brittleness.

Systemic Impairment

Underlying cirrhosis reduces the liver's synthetic reserve, leading to a deficiency in coagulation factors and an inability to manage hypoperfusion injury during hemorrhage.

Therapeutic Management Strategies

Management principles prioritize immediate hemorrhage control followed by definitive oncological treatment.

1. Conservative Treatment

Conservative measures include bed rest, fluid resuscitation, and drug-based hemostasis.

  • Application: Limited to patients in a moribund state, those with extensive metastasis, or as a temporary measure to stabilize a patient for more invasive procedures.

  • Risk: Extremely high mortality and rebleeding rates; it fails to address the primary lesion or the dissemination of cancer cells into the peritoneum.

2. Transcatheter Arterial Embolization (TAE/TACE)

TAE has become a primary tool for managing acute bleeding due to its minimally invasive nature and high hemostatic success rate (53%–100%).

  • Advantages: Performed under local anesthesia; protects normal liver tissue through super-selective embolization; provides a roadmap for subsequent surgery.

  • Complications: Post-embolization syndrome (nausea, pain); potential for increased VEGF expression, which may promote future recurrence.

3. Surgical Intervention

Surgery remains the only potentially curative option, though the timing is critical.

  • Emergency Hepatectomy (within 3 days):

    • Aims for simultaneous hemostasis and radical resection.

    • Associated with high in-hospital mortality (16.5%–100%) and difficulty in assessing liver reserve during shock.

  • Staged Hepatectomy (after 7+ days):

    • Typically follows successful TAE/TACE once vital signs are stable (often 14–42 days post-admission).

    • Clinical Consensus: This is considered the ideal treatment. It reduces perioperative risk and hospital stay.

    • Early vs. Delayed: Completing secondary surgery within eight days of hemostasis (staged early partial hepatectomy) has shown better survival and lower dissemination rates than delayed resection.

4. Ablative Therapies

  • Microwave Coagulation (MWA): Can coagulate tissue at the bleeding point and offers some oncological benefits, potentially reducing peritoneal carcinomatosis.

  • Radiofrequency Ablation (RFA): Less commonly used for initial rupture; more frequently employed for postoperative recurrence.

Prognostic Factors and Survival Data

Research indicates that rHCC should not be viewed as a monolithic "terminal" diagnosis. Survival outcomes vary significantly based on treatment modality and baseline patient health.

Survival Comparison by Treatment 

Study

Surgical OS (1-Year)

TAE/TACE Alone OS (1-Year)

Kwon et al.

88.8%

N/A

Lee et al.

88.7%

40.1%

Zou et al.

54.8%

46.2%

Yang et al.

56.3%

9.1%

Key Prognostic Predictors

  • Tumor Size: Tumors ≥10 cm are independent risk factors for poor overall survival (OS) and recurrence-free survival (RFS).

  • AFP Levels: AFP ≥1000 ng/ml is a significant risk factor, particularly in TACE patients.

  • Clinical State: The presence of hypovolemic shock on admission and BCLC (Barcelona Clinic Liver Cancer) stages are critical predictors.

  • Pathology: The absence of a tumor capsule and high pathological scores negatively impact long-term prognosis.

Conclusion

Spontaneous rupture of HCC is a fatal emergency that requires aggressive, hierarchical management. While current staging systems categorize rHCC as T4 disease, clinical data suggests that patients with stable vital signs and Child-Pugh Grade A or B liver function can achieve favorable long-term survival through a combination of interventional hemostasis and staged surgical resection. Clinicians are encouraged to move away from conservative-only approaches for salvageable patients, as aggressive treatment can significantly prolong life and improve prognostic outcomes.